NCT05741346Phase 2Terminated

Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-01-31Actual

Enrollment · participants28Actual

Source updated2025-10-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-24 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: ~~Proportion~~ of Participants ~~with~~ Treatment ~~Emergent Adverse~~ Events (TEAEs)

+ After

Measure: Number of Participants With Treatment-emergent Events (TEAEs)

Check registry source

Study details

Conditions studied

Paroxysmal Nocturnal Hemoglobinuria

Treatments or interventions studied

BCX9930Drug

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants With Treatment-emergent Events (TEAEs); description: An adverse event (AE) is any untoward medical occurrence in a clinical study participant. No causal relationship with study intervention or with the clinical study itself is implied. An AE could be an unfavorable and unintended sign, symptom (including an abnormal laboratory finding), syndrome, or illness that developed or worsened during the clinical study. A serious adverse event (SAE) is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or other medically important event. An AE is considered treatment emergent if its start date was on or after the date of first dose of study treatment in Study 205 or if the AE was ongoing from the prior study. TEAEs included both serious TEAEs and non-serious TEAEs.; timeFrame: From Day 1 up to 30 days after last dose (up to approximately 100 weeks)

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history